Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Related Keywords

Matthews Davids , ,Harvard Medical School ,Division Of Lymphoma ,Dana Farber Cancer Institute ,Phase 1 2 Bruin Trial Nct03740529 ,Irtobrutinib Jaypirca ,Cll ,Usll ,Hematologic Malignancies ,Richter Transformation ,